Assessment of Drug-Drug Interaction Risk Between Intravenous Fentanyl and the Glecaprevir/Pibrentasvir Combination Regimen in Hepatitis C Patients Using Physiologically Based Pharmacokinetic Modeling and Simulations.

Dwaipayan MukherjeeMichelle CollinsDouglas E DyllaJatinder KaurDimitri SemizarovAnthony MartinezBrian ConwayTipu KhanNael M Mostafa

Published in: Infectious diseases and therapy (2023)

The administration of a therapeutic dose of GLE/PIB has very little effect on the pharmacokinetics of intravenous fentanyl. This negligible increase would not be expected to increase the risk of fentanyl overdose beyond the inherent risks related to the amount and purity of the fentanyl received during recreational use.

Keyphrases

end stage renal disease
ejection fraction
high dose
chronic kidney disease
newly diagnosed
peritoneal dialysis
drug induced
molecular dynamics
computed tomography
patient reported outcomes
patient reported